Please assess the completion status of the following clinical trial:

Trial Title: Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be diagnosed with PMF, PPV-MF or PET-MF according to the 2008 World Health Organization criteria~* Subjects with MF requiring therapy must be classified as high risk OR intermediate risk level 2 according to the prognostic factors defined by the International Working Group~* Subjects with an ECOG performance status of 0, 1, 2 or 3~* Subjects with peripheral blood blast count of \< 10%.~* Subjects who have not previously received treatment with a JAK inhibitor~Exclusion Criteria:~* Subjects with a life expectancy of less than 6 months~* Subjects with inadequate bone marrow reserve as demonstrated by specific clinical laboratory counts~* Subjects with any history of platelet counts \< 50,000/µL or ANC \< 500/µL except during treatment for a myeloproliferative disorder or treatment with cytotoxic therapy for any other reason~* Subjects with inadequate liver or renal function~* Subjects with clinically significant bacterial, fungal, parasitic or viral infection which require therapy~* Subjects with an active malignancy over the previous 5 years except specific skin cancers~* Subjects with severe cardiac conditions~* Subjects who have had splenic irradiation within 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: EXPERIMENTAL): 5 mg tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule
- Best Available Therapy (BAT) (Type: ACTIVE_COMPARATOR): Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.~Patients randomized to BAT were eligible to cross over to receive open-label ruxolitinib after a qualifying progression event, if they met the safety criteria. After the primary analysis in January 2011, patients randomized to receive BAT were allowed to cross over to receive ruxolitinib and move to the extension phase of the study without a qualifying progression event.

Based on this trial design, predict the completion outcome and termination type (if applicable).